**In this Issue**

Highlighted research articles .......... 893

**Research Articles**

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma .......... 920


Précis: The risk variant rs7034162 in NFIB contributes to osteosarcoma metastasis susceptibility.

**Important News Stories Affecting the Community** .......... 896

**Research Watch**

Selected highlights of recent articles of exceptional significance from the cancer literature .......... 901

**Online**

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**Views**

In The Spotlight

Cancer Metastasis: Perivascular Macrophages Under Watch .... 906

E. Kadioglu and M. De Palma

See article, p. 932

Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer .... 909

M.R. Heideman, A. Frei, and N.E. Hynes

See article, p. 944

Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid Leukemia .... 912

P. Do and J.C. Byrd

See article, p. 988

**Mini Review**


A. Ribas

**Highlights of Recent Articles of Exceptional Significance from the Cancer Literature** .... 901

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**In this Issue**

Highlighted research articles .......... 893

**Research Articles**

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma .......... 920


Précis: The risk variant rs7034162 in NFIB contributes to osteosarcoma metastasis susceptibility.

**Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA** ............ 932


Précis: Hyperpermeability of tumor vasculature is dynamic and restricted to the Tumor MicroEnvironment of Metastasis (TMEM).

See commentary, p. 906

**HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance** .......... 944


Précis: HOXB7 is upregulated by MYC-mediated suppression of miR-196a and enhances expression of ER target genes in tamoxifen-resistant breast cancer cells.

See commentary, p. 909
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer ................. 960
Précis: Acquired resistance to EGFR inhibitors can be prevented with dual EGFR and MEK inhibition, which results in prolonged ERK1/2 inhibition and increased apoptosis in EGFR-mutant NSCLC.

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma ............... 972
Précis: Upregulation of MYC in multiple myeloma cells drives DNA damage via replicative stress and ROS induction, and confers sensitivity to ATR inhibitors and small-molecule inducers of ROS.

Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy ................ 988
G.K. Behbehani, N. Samusik, Z.B. Bjornson, W.J. Fantl, B.C. Medeiros, and G.P. Nolan
Précis: High-dimensional analysis of patient-derived AML cells using mass cytometry identifies changes in immunophenotypic patterns and cell-cycle kinetics that are predictive of AML subtype and chemotherapeutic response.

See commentary, p. 912

Tricker, Xu, and colleagues found that combined treatment with the mutant EGFR-selective inhibitor WZ4002 and the MEK inhibitor trametinib delayed the development of acquired resistance in EGFR inhibitor-naïve and EGFR\textsuperscript{T790M}-positive lung cancer cells. WZ4002/trametinib treatment prevented ERK1/2 reactivation and increased apoptosis. Combination treatment was also significantly more effective than WZ4002 alone in suppressing tumor regrowth in xenograft models and a genetically engineered mouse model of EGFR\textsuperscript{T790M}-mutant lung cancer. Although EGFR and ERK inhibition were maintained in the majority of WZ4002/trametinib-resistant tumor nodules, both AKT and S6 were frequently reactivated, and the addition of an mTOR inhibitor restored WZ4002/trametinib sensitivity in vitro and in vivo. These results highlight the potential clinical utility of initial cotargeting of EGFR and MEK to prevent the emergence of acquired resistance in EGFR-mutant lung cancer. For details, please see the article by Tricker, Xu, and colleagues on page 960.
CANCER DISCOVERY

5 (9)


| Updated version | Access the most recent version of this article at: http://cancerdiscovery.aacrjournals.org/content/5/9 |

| E-mail alerts     | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions     | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |